alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › placebo-controlled-phase

placebo-controlled-phase

2 studies tagged placebo-controlled-phase, dated 2011-04-19 to 2023-06-29. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study 2023-06-29
  2. Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial 2011-04-19

Studies

2 studies carry this tag.

Date range

2011 to 2023

Top journals

  • Alzheimer's research & therapy 1
  • EBioMedicine 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study

    ✓ Peer-reviewed alzhub usefulness score 79 out of 100. EBioMedicine 2023-06-29 Treatments

    Between 7 December 2015 and 28 August 2018, 43 participants were randomised.

  2. Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. Alzheimer's research & therapy 2011-04-19 Treatments

    Masitinib administered as add-on therapy to standard care during 24 weeks was associated with slower cognitive decline in Alzheimer's disease, with an acceptable tolerance profile.

All topic tags with their study counts